Literature DB >> 7051034

Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575).

K V Honn, J Meyer, G Neagos, T Henderson, C Westley, V Ratanatharathorn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7051034

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


× No keyword cloud information.
  7 in total

1.  Phase I and pharmacologic evaluation of nafazatrom in patients with cancer.

Authors:  C D Haas; L H Baker; L J Evans
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.

Authors:  C D Haas; G W Kyle; J D Crissman; M F Schaldenbrand
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine.

Authors:  K V Honn; J M Onoda; C A Diglio; M M Carufel; J D Taylor; B F Sloane
Journal:  Clin Exp Metastasis       Date:  1984 Jan-Mar       Impact factor: 5.150

Review 4.  Theories on the metastatic process and possible therapeutic options.

Authors:  P J Effert; T G Strohmeyer
Journal:  Urol Res       Date:  1995

Review 5.  Cell detachment and metastasis.

Authors:  L Weiss; P M Ward
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

6.  Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions.

Authors:  Mary B Casey; Shuya Zhang; Long Jin; Sabine Kajita; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 7.  Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis.

Authors:  Gianenrico Rovati; Annalisa Contursi; Annalisa Bruno; Stefania Tacconelli; Patrizia Ballerini; Paola Patrignani
Journal:  Cells       Date:  2022-02-18       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.